Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 211,316 |
|
|||||
| News | - | ||||||
| Day High | 1.34 | Low High |
|||||
| Day Low | 1.23 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Immunic Inc | IMUX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.045 | 3.61% | 1.29 | 17:30:49 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.24 | 1.23 | 1.34 | 1.29 | 1.245 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,309 | 211,316 | US$ 1.28 | US$ 271,110 | - | 0.9451 - 3.11 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 17:30:49 | formt | 300 | US$ 1.29 | USD |
Immunic Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 116.01M | 89.93M | - | 0 | -93.61M | -1.04 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Immunic News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IMUX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.27 | 1.34 | 1.18 | 1.25 | 414,852 | 0.02 | 1.57% |
| 1 Month | 1.20 | 1.44 | 1.17 | 1.27 | 240,467 | 0.09 | 7.50% |
| 3 Months | 1.22 | 1.64 | 1.17 | 1.35 | 404,221 | 0.07 | 5.74% |
| 6 Months | 1.06 | 1.73 | 1.03 | 1.31 | 643,549 | 0.23 | 21.70% |
| 1 Year | 1.87 | 3.11 | 0.9451 | 1.62 | 780,147 | -0.58 | -31.02% |
| 3 Years | 12.98 | 15.12 | 0.9451 | 4.14 | 885,642 | -11.69 | -90.06% |
| 5 Years | 10.05 | 28.2138 | 0.9451 | 5.80 | 617,365 | -8.76 | -87.16% |
Immunic Description
| Immunic Inc is a clinical stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, IMU-935 is an inverse agonist of RORyt and IMU-856 targets the restoration of the intestinal barrier function. |
